Forward catalyst · PFE

mevrometostat

Sponsor Pfizer INC · listed as PFE

READOUT Phase 3 Confidence: medium Source: clinicaltrials

mevrometostat is a clinical-stage drug asset sponsored by Pfizer INC, listed as PFE. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 2, 2026 (day precision, medium confidence), tied to trial NCT06629779. The asset is in Phase 3 and currently recruiting, studied in Metastatic Castration-Resistant Prostate Cancer. It appears across 3 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT

Expected date2026-12-02

As disclosedDec 2, 2026

Date precisionday

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT06629779

PhasePHASE3

StatusRECRUITING

Lead sponsorPfizer

Listed asPFE

Condition(s)Metastatic Castration-Resistant Prostate Cancer

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More PFE catalysts